menu
    • menu
    [{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Veligrotug","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioPharma \/ Viridian Therapeutics"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Enavate Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Enavate Sciences"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ Morgan Stanley"},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Series C Financing","leadProduct":"Obexelimab","moa":"CD19\/Fc-gammaRllb","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zenas BioPharma \/ SR One Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioPharma \/ SR One Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Zenas BioPharma

    Menu

    Zenas BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zenas BioPharma Completes Phase 3 Trial Enrollment for Obexelimab

                            Details : ZB012 (obexelimab), a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. It is being investigated for Immunoglobulin G4-Related Disease.

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

                            Details : The net proceeds to advance the clinical development of its lead asset ZB012 (obexelimab), a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19.

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $258.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Zenas BioPharma Closes Full Exercise Of Underwriters’ Option in IPO

                            Details : The net proceeds to advance the clinical development of its lead asset ZB012 (obexelimab), a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19.

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 19, 2024

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $258.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : SR One Capital Management

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Zenas BioPharma Upsizes $200 Million Series C Financing for Immunology Programs

                            Details : The company plans to advance the clinical development of ZB012 (obexelimab), a novel bifunctional antibody with first-in-class potential that inhibits CD19-expressing B-cell lineages.

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 05, 2024

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : SR One Capital Management

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Imm...

                            Details : ZB-O12 (obexelimab) is an investigational Phase 3-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19 and generates an encouraging treatment effect in patients with multiple autoimmune diseases...

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 01, 2023

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

                            Details : The collaboration aims to develop and commercialize ZB-O12 (obexelimab), an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcγRIIb, for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Ko...

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : $50.0 million

                            May 09, 2023

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Viridian Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid E...

                            Details : ZB001 (Viridian VRDN-001) is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of TED.

                            Product Name : VRDN-001

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 05, 2022

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Viridian Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Enavate Sciences

                            Deal Size : $118.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

                            Details : ZB-O12 (obexelimab) is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. Simultaneous binding to CD19 and FcƳRIIB by obexelimab mimics a natural antigen-antibody complex and down-regulates B-cel...

                            Product Name : ZB012

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 11, 2022

                            Lead Product(s) : Obexelimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Enavate Sciences

                            Deal Size : $118.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            Zenas BioPharma

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Viridian Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Di...

                            Details : Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater China area from Viridian Therapeutics in 2020.

                            Product Name : VRDN-001

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 08, 2022

                            Lead Product(s) : Veligrotug

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Viridian Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth